Related Experiment Video

Updated: Aug 2, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors

Kinnosuke Matsumoto1,2, Yujiro Naito1, Takayuki Shiroyama1

  • 1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.

Cancer Science
|April 21, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
PD‐1 inhibitorsnon‐small cell lung cancerperipheral immune monitoringramucirumabsequential treatment

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Experiment Videos

Last Updated: Aug 2, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

JTO clinical and research reports·2026

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

JTO clinical and research reports·2026

Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.

Mediastinum (Hong Kong, China)·2026

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Thoracic cancer·2026

Immunopathophysiology of immune checkpoint inhibitor-related pneumonitis: insights from multi-omics and immune profiling.

Immunological medicine·2026

WDR12 Promotes Glucose Metabolism via PFKFB4 Upregulation in Gastric Cancer.

Cancer science·2026

Treatment-Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure.

Cancer science·2026

Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.

Cancer science·2026

Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial.

Cancer science·2026

A CECT-Based 2PI System as a Novel Noninvasive Prognostic Tool for Hepatocellular Carcinoma: A Dual-Validation Study.

Cancer science·2026

Triggering SORL1 Expression Restricts ccRCC Progression by Inducing Ubiquitination-Mediated c-Myc Degradation.

Cancer science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us